Do analysts prefer OPTX or NAUT?

Nautilus Biotechnology has a consensus target price of $4.00, suggesting a potential upside of 131.21%. Given Nautilus Biotechnology's stronger consensus rating and higher possible upside, analysts plainly believe Nautilus Biotechnology is more favorable than Syntec Optics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Syntec Optics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Nautilus Biotechnology 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Nautilus Biotechnology (NAUT) Competitors

$1.73 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$1.80 +0.08 (+4.34%)

As of 07/2/2026 06:42 PM Eastern

Compare

NAUT vs. TRNS, FEIM, CTKB, OPTX, and MASS

Should you buy Nautilus Biotechnology stock or one of its competitors? MarketBeat compares Nautilus Biotechnology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nautilus Biotechnology include Transcat (TRNS), Frequency Electronics (FEIM), Cytek Biosciences (CTKB), Syntec Optics (OPTX), and 908 Devices (MASS). These companies are all part of the "measuring and control equipment" industry.

How does Nautilus Biotechnology compare to Transcat?

Transcat (NASDAQ:TRNS) and Nautilus Biotechnology (NASDAQ:NAUT) are both small-cap measuring and control equipment companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, media sentiment, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.

Transcat currently has a consensus price target of $105.33, indicating a potential upside of 18.31%. Nautilus Biotechnology has a consensus price target of $4.00, indicating a potential upside of 131.21%. Given Nautilus Biotechnology's higher possible upside, analysts plainly believe Nautilus Biotechnology is more favorable than Transcat.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Transcat	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Nautilus Biotechnology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

98.3% of Transcat shares are held by institutional investors. Comparatively, 50.7% of Nautilus Biotechnology shares are held by institutional investors. 2.8% of Transcat shares are held by company insiders. Comparatively, 41.1% of Nautilus Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Transcat has a beta of 0.69, meaning that its share price is 31% less volatile than the broader market. Comparatively, Nautilus Biotechnology has a beta of 0.8, meaning that its share price is 20% less volatile than the broader market.

In the previous week, Transcat's average media sentiment score of 0.00 equaled Nautilus Biotechnology'saverage media sentiment score.

Company	Overall Sentiment
Transcat	Neutral
Nautilus Biotechnology	Neutral

Transcat has higher revenue and earnings than Nautilus Biotechnology. Nautilus Biotechnology is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Transcat	$331.88M	2.51	$5.38M	$0.58	153.50
Nautilus Biotechnology	N/A	N/A	-$59M	-$0.46	N/A

Transcat has a net margin of 1.62% compared to Nautilus Biotechnology's net margin of 0.00%. Transcat's return on equity of 5.84% beat Nautilus Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Transcat	1.62%	5.84%	3.78%
Nautilus Biotechnology	N/A	-35.04%	-29.16%

Summary

Transcat beats Nautilus Biotechnology on 11 of the 14 factors compared between the two stocks.

How does Nautilus Biotechnology compare to Frequency Electronics?

Frequency Electronics (NASDAQ:FEIM) and Nautilus Biotechnology (NASDAQ:NAUT) are both small-cap measuring and control equipment companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership and valuation.

58.6% of Frequency Electronics shares are held by institutional investors. Comparatively, 50.7% of Nautilus Biotechnology shares are held by institutional investors. 28.0% of Frequency Electronics shares are held by insiders. Comparatively, 41.1% of Nautilus Biotechnology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Frequency Electronics has a net margin of 10.78% compared to Nautilus Biotechnology's net margin of 0.00%. Frequency Electronics' return on equity of 12.69% beat Nautilus Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Frequency Electronics	10.78%	12.69%	7.84%
Nautilus Biotechnology	N/A	-35.04%	-29.16%

Frequency Electronics has higher revenue and earnings than Nautilus Biotechnology. Nautilus Biotechnology is trading at a lower price-to-earnings ratio than Frequency Electronics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Frequency Electronics	$69.81M	9.10	$23.69M	$0.75	86.12
Nautilus Biotechnology	N/A	N/A	-$59M	-$0.46	N/A

Frequency Electronics presently has a consensus target price of $43.67, indicating a potential downside of 32.39%. Nautilus Biotechnology has a consensus target price of $4.00, indicating a potential upside of 131.21%. Given Nautilus Biotechnology's higher possible upside, analysts plainly believe Nautilus Biotechnology is more favorable than Frequency Electronics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Frequency Electronics	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.00
Nautilus Biotechnology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Frequency Electronics has a beta of 0.71, indicating that its share price is 29% less volatile than the broader market. Comparatively, Nautilus Biotechnology has a beta of 0.8, indicating that its share price is 20% less volatile than the broader market.

In the previous week, Frequency Electronics had 3 more articles in the media than Nautilus Biotechnology. MarketBeat recorded 3 mentions for Frequency Electronics and 0 mentions for Nautilus Biotechnology. Frequency Electronics' average media sentiment score of 0.00 equaled Nautilus Biotechnology'saverage media sentiment score.

Company	Overall Sentiment
Frequency Electronics	Neutral
Nautilus Biotechnology	Neutral

Summary

Frequency Electronics beats Nautilus Biotechnology on 11 of the 14 factors compared between the two stocks.

How does Nautilus Biotechnology compare to Cytek Biosciences?

Nautilus Biotechnology (NASDAQ:NAUT) and Cytek Biosciences (NASDAQ:CTKB) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings, media sentiment and valuation.

50.7% of Nautilus Biotechnology shares are held by institutional investors. Comparatively, 69.5% of Cytek Biosciences shares are held by institutional investors. 41.1% of Nautilus Biotechnology shares are held by company insiders. Comparatively, 10.4% of Cytek Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Nautilus Biotechnology has higher earnings, but lower revenue than Cytek Biosciences. Cytek Biosciences is trading at a lower price-to-earnings ratio than Nautilus Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nautilus Biotechnology	N/A	N/A	-$59M	-$0.46	N/A
Cytek Biosciences	$201.49M	2.94	-$66.54M	-$0.57	N/A

Nautilus Biotechnology has a net margin of 0.00% compared to Cytek Biosciences' net margin of -36.25%. Cytek Biosciences' return on equity of -10.07% beat Nautilus Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nautilus Biotechnology	N/A	-35.04%	-29.16%
Cytek Biosciences	-36.25%	-10.07%	-7.56%

Nautilus Biotechnology has a beta of 0.8, indicating that its share price is 20% less volatile than the broader market. Comparatively, Cytek Biosciences has a beta of 1.17, indicating that its share price is 17% more volatile than the broader market.

Nautilus Biotechnology presently has a consensus target price of $4.00, suggesting a potential upside of 131.21%. Cytek Biosciences has a consensus target price of $5.69, suggesting a potential upside of 23.91%. Given Nautilus Biotechnology's higher probable upside, equities research analysts plainly believe Nautilus Biotechnology is more favorable than Cytek Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nautilus Biotechnology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Nautilus Biotechnology's average media sentiment score of 0.00 equaled Cytek Biosciences'average media sentiment score.

Company	Overall Sentiment
Nautilus Biotechnology	Neutral
Cytek Biosciences	Neutral

Summary

Cytek Biosciences beats Nautilus Biotechnology on 7 of the 13 factors compared between the two stocks.

How does Nautilus Biotechnology compare to Syntec Optics?

Syntec Optics (NASDAQ:OPTX) and Nautilus Biotechnology (NASDAQ:NAUT) are both small-cap measuring and control equipment companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation, media sentiment and analyst recommendations.

50.7% of Nautilus Biotechnology shares are owned by institutional investors. 0.8% of Syntec Optics shares are owned by insiders. Comparatively, 41.1% of Nautilus Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Syntec Optics has higher revenue and earnings than Nautilus Biotechnology. Syntec Optics is trading at a lower price-to-earnings ratio than Nautilus Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syntec Optics	$28.08M	15.61	-$1.79M	-$0.08	N/A
Nautilus Biotechnology	N/A	N/A	-$59M	-$0.46	N/A

In the previous week, Syntec Optics had 2 more articles in the media than Nautilus Biotechnology. MarketBeat recorded 2 mentions for Syntec Optics and 0 mentions for Nautilus Biotechnology. Syntec Optics' average media sentiment score of 1.00 beat Nautilus Biotechnology's score of 0.00 indicating that Syntec Optics is being referred to more favorably in the media.

Company	Overall Sentiment
Syntec Optics	Positive
Nautilus Biotechnology	Neutral

Syntec Optics has a beta of -0.86, indicating that its stock price is 186% less volatile than the broader market. Comparatively, Nautilus Biotechnology has a beta of 0.8, indicating that its stock price is 20% less volatile than the broader market.

Nautilus Biotechnology has a net margin of 0.00% compared to Syntec Optics' net margin of -10.95%. Syntec Optics' return on equity of -30.86% beat Nautilus Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syntec Optics	-10.95%	-30.86%	-12.35%
Nautilus Biotechnology	N/A	-35.04%	-29.16%

Nautilus Biotechnology has a consensus target price of $4.00, suggesting a potential upside of 131.21%. Given Nautilus Biotechnology's stronger consensus rating and higher possible upside, analysts plainly believe Nautilus Biotechnology is more favorable than Syntec Optics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syntec Optics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Nautilus Biotechnology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Nautilus Biotechnology beats Syntec Optics on 8 of the 15 factors compared between the two stocks.

How does Nautilus Biotechnology compare to 908 Devices?

908 Devices (NASDAQ:MASS) and Nautilus Biotechnology (NASDAQ:NAUT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.

908 Devices has higher revenue and earnings than Nautilus Biotechnology. 908 Devices is trading at a lower price-to-earnings ratio than Nautilus Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
908 Devices	$56.20M	5.85	$19.49M	-$1.00	N/A
Nautilus Biotechnology	N/A	N/A	-$59M	-$0.46	N/A

908 Devices has a beta of 0.63, meaning that its share price is 37% less volatile than the broader market. Comparatively, Nautilus Biotechnology has a beta of 0.8, meaning that its share price is 20% less volatile than the broader market.

In the previous week, 908 Devices' average media sentiment score of 0.63 beat Nautilus Biotechnology's score of 0.00 indicating that 908 Devices is being referred to more favorably in the media.

Company	Overall Sentiment
908 Devices	Positive
Nautilus Biotechnology	Neutral

88.1% of 908 Devices shares are owned by institutional investors. Comparatively, 50.7% of Nautilus Biotechnology shares are owned by institutional investors. 28.2% of 908 Devices shares are owned by insiders. Comparatively, 41.1% of Nautilus Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

908 Devices presently has a consensus target price of $12.00, indicating a potential upside of 38.09%. Nautilus Biotechnology has a consensus target price of $4.00, indicating a potential upside of 131.21%. Given Nautilus Biotechnology's higher possible upside, analysts plainly believe Nautilus Biotechnology is more favorable than 908 Devices.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
908 Devices	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nautilus Biotechnology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Nautilus Biotechnology has a net margin of 0.00% compared to 908 Devices' net margin of -62.40%. 908 Devices' return on equity of -14.03% beat Nautilus Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
908 Devices	-62.40%	-14.03%	-10.40%
Nautilus Biotechnology	N/A	-35.04%	-29.16%

Summary

908 Devices and Nautilus Biotechnology tied by winning 6 of the 12 factors compared between the two stocks.

Get Nautilus Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NAUT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NAUT vs. The Competition

Export

Metric	Nautilus Biotechnology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$219.85M	$3.78B	$7.18B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.51%
P/E Ratio	-3.76	21.61	28.02	24.70
Price / Sales	N/A	331.74	535.36	97.93
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	1.40	8.66	10.96	6.46
Net Income	-$59M	$23.81M	$3.57B	$337.01M
7 Day Performance	-13.50%	3.39%	2.12%	1.69%
1 Month Performance	-27.62%	10.81%	5.25%	3.81%
1 Year Performance	110.46%	62.61%	33.29%	23.90%

Nautilus Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NAUT Nautilus Biotechnology	2.9751 of 5 stars	$1.73 flat	$4.00 +131.2%	+110.5%	$219.85M	N/A	N/A	130
TRNS Transcat	3.129 of 5 stars	$92.77 +1.6%	$105.33 +13.5%	-0.9%	$852.62M	$331.88M	159.95	1,413	Gap Up
FEIM Frequency Electronics	0.4869 of 5 stars	$66.35 +7.4%	$43.67 -34.2%	+196.3%	$607.94M	$69.81M	88.47	200	News Coverage Positive News Upcoming Earnings Analyst Upgrade
CTKB Cytek Biosciences	2.5123 of 5 stars	$4.43 +2.1%	$5.69 +28.4%	+22.1%	$560.48M	$201.49M	N/A	500	Positive News
OPTX Syntec Optics	0.2944 of 5 stars	$12.45 +17.7%	N/A	+691.3%	$426.16M	$28.08M	N/A	3	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NAUT) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nautilus Biotechnology (NAUT) Competitors

NAUT vs. TRNS, FEIM, CTKB, OPTX, and MASS

How does Nautilus Biotechnology compare to Transcat?

Summary

How does Nautilus Biotechnology compare to Frequency Electronics?

Summary

How does Nautilus Biotechnology compare to Cytek Biosciences?

Summary

How does Nautilus Biotechnology compare to Syntec Optics?

Summary

How does Nautilus Biotechnology compare to 908 Devices?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NAUT vs. The Competition

Nautilus Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nautilus Biotechnology (NAUT) Competitors

NAUT vs. TRNS, FEIM, CTKB, OPTX, and MASS

How does Nautilus Biotechnology compare to Transcat?

Do analysts rate TRNS or NAUT?

Do institutionals and insiders believe in TRNS or NAUT?

Which has more volatility and risk, TRNS or NAUT?

Does the media refer more to TRNS or NAUT?

Which has stronger valuation and earnings, TRNS or NAUT?

Is TRNS or NAUT more profitable?

Summary

How does Nautilus Biotechnology compare to Frequency Electronics?

Do insiders and institutionals believe in FEIM or NAUT?

Is FEIM or NAUT more profitable?

Which has stronger valuation & earnings, FEIM or NAUT?

Do analysts recommend FEIM or NAUT?

Which has more risk and volatility, FEIM or NAUT?

Does the media refer more to FEIM or NAUT?

Summary

How does Nautilus Biotechnology compare to Cytek Biosciences?

Do insiders and institutionals hold more shares of NAUT or CTKB?

Which has stronger valuation & earnings, NAUT or CTKB?

Is NAUT or CTKB more profitable?

Which has more volatility and risk, NAUT or CTKB?

Do analysts rate NAUT or CTKB?

Does the media prefer NAUT or CTKB?

Summary

How does Nautilus Biotechnology compare to Syntec Optics?

Do insiders & institutionals hold more shares of OPTX or NAUT?

Which has stronger valuation and earnings, OPTX or NAUT?

Does the media prefer OPTX or NAUT?

Which has more volatility and risk, OPTX or NAUT?

Is OPTX or NAUT more profitable?

Do analysts prefer OPTX or NAUT?

Summary

How does Nautilus Biotechnology compare to 908 Devices?

Which has higher valuation & earnings, MASS or NAUT?

Which has more risk and volatility, MASS or NAUT?

Does the media refer more to MASS or NAUT?

Do insiders and institutionals hold more shares of MASS or NAUT?

Do analysts prefer MASS or NAUT?

Is MASS or NAUT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NAUT vs. The Competition

Nautilus Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools